INSMED Inc Q3 FY2026 earnings call

• Launch Performance: Rensipre launch exceeded all expectations, tracking ahead of internal metrics and benchmarks. The team successfully activated patient and physician interest through efficient media channels.
• Physician Adoption: Of the 25,000+ physicians called on, a small fraction are high prescribers, many of whom are trialists or new users. Positive patient feedback loops are converting trialists into higher-volume prescribers.
• Market Access: Reimbursement approval rates remain strong, historically north of 90%, supporting gross-to-net margins in the low-to-mid 20s.
• International Expansion: Japan launch is proceeding aggressively with ~75 sales reps, adding 50 more next year due to significant opportunity. EU launch remains on hold pending clarity on reimbursability levels.
• Pipeline Progress: INS1033 cleared IND for COPD/UC; TPIP Phase 3 trials initiated for PHILD and PAH, with PPF starting late this year and IPF early next year. Gene therapy programs for DMD and ALS are advancing toward data readouts next year.

The transcript focuses primarily on the commercial performance of Rensipre (Brinsupre). First-year revenue estimates were raised to $1.25–$1.4 billion, outperforming initial benchmarks of $500–$700 million and positioning it among the top 20 launches ever. Peak sales guidance for Rensipre was increased to over $7 billion USD. The company is approaching nearly $2 billion in total annual revenue by year-end, driven by Rensipre, with significant growth expected from EraCase label expansion and future TPIP indications.

• Rensipre First-Year Revenue: Raised estimate to $1.25–$1.4 billion.
• Rensipre Peak Sales: Upward revision to north of $7 billion USD (excluding COPD/asthma comorbid populations).
• Total Company Revenue: Approaching nearly $2 billion in revenue by end of year.
• Long-Term Growth: Expect substantial year-over-year compound annual growth for the next 5–10 years supported by current portfolio and pipeline.
• Update Cadence: Natural break points for guidance updates are August (board strategic offsite) and beginning of the year.

• Competition: Expectation that competitors will take meaningful market share; peak sales estimates already account for this pressure.
• Regulatory/Pricing: Potential price renegotiation from the Inflation Reduction Act (IRA) by 2035; uncertainty around European Union reimbursability.
• Clinical Failures: Previous DPP-1 candidates for CRS and hidradenitis suppurativa failed phase 2; new indications require validation.
• China Innovation: Rising Chinese innovation presents competitive pressure, though current Chinese DPP-1 competitors are behind Insmed's timeline.
• AI Dependency: Acknowledged risk regarding long-term viability of AI technologies.

Q: What specific factors drove the upward revision of Rensipre’s peak sales guidance to over $7 billion? / A: Management cited updated market access data and stronger-than-expected clinical performance compared to other prostanoids. The drug shows superior efficacy, safety, and convenience, allowing higher dosages without parenteral treatment. This positions it as a potential combination therapy partner if competitors succeed, significantly expanding its addressable market beyond initial estimates.

Q: How does management view the potential impact of COPD and asthma comorbid patients on Rensipre’s growth trajectory? / A: This represents a massive untapped opportunity, potentially adding millions of patients to the funnel. Management expects to see early indicators of conversion by mid-next year via data from high-resolution CT scan studies. Capturing these patients is seen as a 'second launch' that could drive further growth beyond the current $7 billion peak estimate.

Q: What is the strategic rationale behind targeting COPD and UC with the second-generation DPP-1 inhibitor INS1033? / A: These indications have robust preclinical animal models, unlike previous failures which lacked such backing. INS1033 is positioned as a first-in-class complement to existing therapies rather than a replacement. Early Phase 1 data is expected next year, with a focus on validating efficacy in emphysema-type phenotypes and ulcerative colitis.

Q: Can you provide an update on the gene therapy pipeline, specifically for DMD and ALS? / A: Data readouts are expected next year. For DMD, results will include a comprehensive mosaic of dystrophin expression, transduction efficiency, and physical performance metrics. For ALS, data will assess efficacy in both SOD1 mutation and sporadic cases. These platforms aim to establish first-in-class status in rare diseases, leveraging acquired technology from San Diego and Cambridge.

Q: How is Insmed integrating AI into its operations, and what role does it play in strategy? / A: AI is embedded across research, commercial, and clinical functions, including de-immunization design and patient finding. Management uses custom AI engines for strategic reflection and forecasting analysis. While proud of internal adoption, they acknowledge external risks associated with rapid AI advancements impacting the broader industry.